Tirzepatide UK: NHS price and private costs

If you are in the UK and trying to work out what tirzepatide (Mounjaro) actually costs, the answer depends entirely on which door you walk through. NHS access runs through two separate NICE technology appraisals with different eligibility criteria. Private prescription costs vary by dose strength and clinic. And the NHS price itself is not published: Eli Lilly and NHS England struck a commercial-in-confidence arrangement when TA924 was approved, so the figure the NHS actually pays is not in the public domain.^[1] This article maps what is known, what is not, and what that means if you are trying to budget for treatment.

For the full compound profile, including mechanism, clinical evidence, and cross-country regulatory status, see the tirzepatide peptide page. For the broader UK regulatory framework that governs all medicines on this site, see the UK regulation hub. For comparison with how semaglutide is priced and accessed in the UK, see the semaglutide peptide page.

The two NHS routes: TA924 (type-2 diabetes) and TA1026 (obesity)

Mounjaro holds an MHRA marketing authorisation for two indications: managing type-2 diabetes in adults whose blood glucose is inadequately controlled, and managing overweight or obesity in adults as an adjunct to a reduced-calorie diet and increased physical activity.^[2] Both indications are authorised. But NHS access to each runs through a separate technology appraisal, and the two appraisals have materially different eligibility criteria.

TA924: tirzepatide for type-2 diabetes (October 2023)

NICE TA924, published in October 2023, recommends tirzepatide as an option for treating type-2 diabetes in adults when triple therapy combining metformin and two other oral antidiabetic drugs has not achieved adequate glycaemic control, or when insulin therapy is clinically inappropriate or unacceptable to the patient.^[1] The trial evidence underpinning the appraisal is primarily the SURPASS programme, including SURPASS-2, the head-to-head against semaglutide 1 mg, where tirzepatide at the 10 mg and 15 mg doses produced greater HbA1c reductions.^[3]

The NHS prescribes tirzepatide under TA924 for as long as glycaemic targets continue to be met. Patients typically have an HbA1c at or above 58 mmol/mol (7.5%) at the point of prescribing and have cycled through at least two prior drug classes. The appraisal was implemented through an eMIT (electronic Medicines Integrative Tendering) contract between NHS England and Eli Lilly, which means the NHS pays a confidential discounted price rather than the public list price.

TA1026: tirzepatide for managing overweight and obesity (December 2024)

NICE TA1026, published in December 2024, recommends tirzepatide as an option for managing overweight and obesity within specialist NHS weight-management services, alongside a reduced-calorie diet and increased physical activity.^[4] The eligibility criteria in TA1026 are stricter than the marketing authorisation alone. The appraisal recommends tirzepatide for adults with a BMI of 35 or above plus at least one weight-related comorbidity, or a BMI between 30 and 34.9 where the comorbidity meets specific severity thresholds. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, lower BMI thresholds apply in line with the marketing authorisation.

TA1026 also imposes a service-delivery constraint that TA924 does not. Prescribing must take place within specialist weight-management services rather than through open GP prescribing. Commissioning is being phased in across integrated care boards, and service capacity varies. Some ICBs have waiting lists. Treatment under TA1026 is time-limited: the current guidance expects a reassessment at two years, and continued prescribing depends on maintained clinical benefit.

The NHS price: commercial-in-confidence

The price NHS England pays for Mounjaro under the TA924 eMIT contract is not published. NICE technology appraisals that involve a commercial arrangement between the manufacturer and NHS England routinely contain a confidential rebate or patient access scheme that reduces the effective cost below the list price. The TA924 guidance document states that tirzepatide is recommended subject to a commercial arrangement with NHS England, but the arrangement details are withheld from the published appraisal.^[1]

What is in the public domain is the pen format. Mounjaro is available in six KwikPen strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all as solution for injection in a pre-filled pen, manufactured by Eli Lilly and Company Limited.

Patients prescribed Mounjaro on the NHS pay only the standard NHS prescription charge (currently £9.90 per item in England, with exemptions for low-income patients, those with type-2 diabetes, and others on the statutory exemption list).^[5] The NHS price to the organisation, rather than the patient, is what the commercial arrangement governs. That figure is not published.

Private prescription costs

Mounjaro is available on private prescription from UK-registered clinics and pharmacies.^[5] Because private pricing is set by individual providers and fluctuates with supply and demand, any figure here reflects observable market patterns rather than an official price list. Across UK private providers in 2025 and 2026, monthly costs for Mounjaro pens have been quoted at roughly £149 to £250 for lower dose strengths (2.5 mg and 5 mg), rising to £200 to £400 for the higher maintenance doses (10 mg to 15 mg). These figures are consistent with the range cited in published reporting on private GLP-1 prescribing in the UK.

Private prescribers typically include an initial consultation fee (ranging from around £50 to £200 depending on the clinic model), ongoing monitoring appointments, and sometimes a bundled-care package covering the pen, consultation, and follow-up. Comparing the headline pen price alone across providers can therefore be misleading: a lower pen price with additional consultation charges may cost more in total than a higher pen price that includes monitoring.

The NHS.UK tirzepatide page warns that anyone seeking the medicine on a private basis should buy from a registered UK pharmacy.^[5] A July 2026 MHRA safety reminder specifically warned that GLP-1 medicines including Mounjaro are offered by unregulated sellers including beauty salons and social media accounts, and that counterfeit pre-filled pens have been found in the UK market.^[7] The General Pharmaceutical Council's register allows patients to confirm whether a pharmacy is registered before buying.

Supply shortages and what they mean for pricing

Mounjaro experienced supply pressures at various points between its UK launch in late 2023 and 2025, driven by global manufacturing capacity and high demand. Supply constraints of this kind do not change the NHS reimbursement arrangement or the standard NHS prescription charge that patients pay. But they do affect availability in practice: a pharmacy without stock cannot dispense, and patients sometimes have to contact multiple pharmacies or wait for restocking.^[2]

In the private market, supply pressure has at points pushed private clinic prices upward, and some providers have added priority-access fees or waitlists. These are market dynamics rather than any change to the NICE-recommended or MHRA-authorised product, and they vary by provider and period. If you are buying privately, it is worth confirming that stock is available before paying any upfront fee.

The MHRA tracks medicine supply problems and publishes alerts through its supply disruption monitoring process. As of the date of this article no formal supply disruption alert for Mounjaro is listed on the MHRA alerts register.^[6]

What patients cannot do: import from abroad or use compounders

A recurring question in online forums is whether tirzepatide can be sourced more cheaply by importing it from a country where the list price is lower, or whether a UK compounding pharmacy can prepare it at lower cost. Both routes are closed.

On personal import: UK rules permit an individual to bring a personal supply of a medicine into the UK for their own use, up to a maximum three-month supply.^[8] But tirzepatide is a prescription-only medicine in the UK. You cannot lawfully possess or use a prescription-only medicine without a valid UK prescription, regardless of where you obtained it. Importing a prescription-only medicine without a prescription does not become legal simply because it is for personal use. The medicine arriving from abroad would also lack MHRA-approved labelling and quality assurance.

On compounding: UK compounding law (the unlicensed specials framework) allows a licensed prescriber to request an unlicensed preparation for a specific named patient, where no suitable licensed alternative exists. Tirzepatide has a suitable licensed alternative: Mounjaro, which holds an MHRA marketing authorisation. The specials framework is not available where a licensed product already exists for the indication. This is the key difference from the US situation, where FDA compounding policy allowed pharmacies to compound tirzepatide during a period when the branded product was listed as in shortage. The UK does not have a comparable shortage-based compounding route.

The split between TA924 and TA1026 matters practically

A patient with type-2 diabetes and obesity can be eligible under TA924 (the diabetes route) but not under TA1026 (the obesity route), or vice versa, depending on their clinical profile and what service they are referred to. The two routes operate in different clinical settings: TA924 typically runs through a diabetes clinic or GP with a diabetes-oriented prescribing pathway; TA1026 runs through specialist weight-management services. Being eligible under one does not transfer to the other.

For patients sitting outside both sets of criteria, the options are a private prescription (at the costs described above) or waiting to see whether their clinical picture changes to meet the eligibility thresholds. Attempting to obtain tirzepatide without a prescription from any source is both unlawful and carries meaningful safety risk, particularly given documented counterfeit activity in the UK market.

What we do not yet know

The NHS price paid under the TA924 commercial arrangement is unlikely to become public while the contract is active. The TA1026 obesity rollout is still in its early phase: service capacity varies by ICB, and the two-year reassessment data on long-term prescribing patterns under that TA will take time to accumulate. Whether NICE will appraise the obstructive sleep apnea indication (approved by the FDA for Zepbound in December 2024 based on the SURMOUNT-OSA trial) is an open question; no NICE appraisal has been announced for that indication as of July 2026.

We update this page when the UK pricing or access picture changes. For the clinical evidence overview, see the tirzepatide peptide page. For the regulatory landscape across other countries, see the UK regulation hub. If you are considering tirzepatide for weight management or type-2 diabetes, that conversation belongs with a clinician who can assess whether you meet the NICE eligibility criteria and what the appropriate prescribing pathway is for your situation.